Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does MEPOLIZUMAB Cause Condition aggravated? 2,304 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 2,304 reports of Condition aggravated have been filed in association with MEPOLIZUMAB (Nucala). This represents 5.4% of all adverse event reports for MEPOLIZUMAB.

2,304
Reports of Condition aggravated with MEPOLIZUMAB
5.4%
of all MEPOLIZUMAB reports
581
Deaths
1,224
Hospitalizations

How Dangerous Is Condition aggravated From MEPOLIZUMAB?

Of the 2,304 reports, 581 (25.2%) resulted in death, 1,224 (53.1%) required hospitalization, and 587 (25.5%) were considered life-threatening.

Is Condition aggravated Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for MEPOLIZUMAB. However, 2,304 reports have been filed with the FAERS database.

What Other Side Effects Does MEPOLIZUMAB Cause?

Asthma (11,033) Dyspnoea (9,192) Wheezing (6,093) Product dose omission issue (5,873) Cough (4,577) Pneumonia (4,107) Therapeutic product effect incomplete (4,106) Drug ineffective (3,880) Loss of personal independence in daily activities (3,566) Fatigue (2,656)

What Other Drugs Cause Condition aggravated?

TOFACITINIB (16,925) INFLIXIMAB (16,616) DUPILUMAB (16,459) ETANERCEPT (15,897) METHOTREXATE (14,938) ADALIMUMAB (13,527) PREDNISONE (10,751) INFLIXIMAB-DYYB (10,275) HYDROXYCHLOROQUINE (8,848) RITUXIMAB (8,627)

Which MEPOLIZUMAB Alternatives Have Lower Condition aggravated Risk?

MEPOLIZUMAB vs MEPROBAMATE MEPOLIZUMAB vs MERCAPTOPURINE MEPOLIZUMAB vs MEROPENEM MEPOLIZUMAB vs MEROPENEM ANHYDROUS MEPOLIZUMAB vs MESALAMINE

Related Pages

MEPOLIZUMAB Full Profile All Condition aggravated Reports All Drugs Causing Condition aggravated MEPOLIZUMAB Demographics